July 23, 2025Journal of Addictive Diseases

Coenzyme Q10 as an adjunctive treatment for substance use disorders: a preclinical review

View Full Paper

Ask AI

Bookmark

Coenzyme Q10 shows potential as an adjunctive treatment for substance use disorders, focusing on its role in reducing neurotoxicity.
Preclinical studies reveal that CoQ10 supplementation decreases apoptosis and improves behavioral outcomes in addiction models.
Research indicates challenges like low bioavailability hinder CoQ10's effectiveness but it safely complements existing treatments.
Further studies are necessary to optimize CoQ10 for better clinical application in managing substance use disorders.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review highlights coenzyme Q10's potential to reduce oxidative stress and enhance mitochondrial function in substance use disorders, indicating its therapeutic promise.

Cite This Study

Adabi et al. (2025) studied this question.

synapsesocial.com/papers/689a0621e6551bb0af8cdce1 https://doi.org/10.1080/10550887.2025.2521561

View Full Paper

Ask AI

Bookmark

Implication

Review highlights coenzyme Q10's potential to reduce oxidative stress and enhance mitochondrial function in substance use disorders, indicating its therapeutic promise.

Coenzyme Q10 as an adjunctive treatment for substance use disorders: a preclinical review

Key Points

Discussion

Implication

Cite This Study

Coenzyme Q10 as an adjunctive treatment for substance use disorders: a preclinical review

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading